Natera (NASDAQ:NTRA) Price Target Raised to $330.00

Natera (NASDAQ:NTRA) had its target price lifted by Canaccord Genuity Group from $285.00 to $330.00 in a research report report published on Tuesday morning, MarketBeat Ratings reports. The brokerage currently has a buy rating on the medical research company’s stock.

A number of other research analysts have also recently issued reports on NTRA. Barclays lowered their price target on shares of Natera from $280.00 to $260.00 and set an “overweight” rating for the company in a research report on Wednesday, June 24th. Robert W. Baird set a $265.00 target price on shares of Natera in a research note on Friday, May 8th. Wells Fargo & Company lifted their target price on shares of Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a report on Friday, May 8th. Guggenheim boosted their price target on Natera from $270.00 to $290.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Finally, BTIG Research set a $275.00 price objective on Natera and gave the company a “buy” rating in a research note on Wednesday, June 24th. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $267.83.

Natera Stock Down 2.7%

NASDAQ NTRA opened at $269.83 on Tuesday. Natera has a twelve month low of $131.81 and a twelve month high of $288.04. The firm has a market capitalization of $38.64 billion, a PE ratio of -165.54 and a beta of 1.51. The stock’s 50 day moving average is $232.43 and its 200 day moving average is $220.05.

Insider Buying and Selling

In related news, Director Roelof Botha sold 78,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $220.31, for a total value of $17,184,180.00. Following the transaction, the director directly owned 1,076,198 shares of the company’s stock, valued at approximately $237,097,181.38. This represents a 6.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Solomon Moshkevich sold 3,405 shares of the stock in a transaction on Friday, May 1st. The shares were sold at an average price of $203.69, for a total value of $693,564.45. Following the sale, the insider owned 142,295 shares in the company, valued at approximately $28,984,068.55. This represents a 2.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 178,872 shares of company stock worth $39,627,696 over the last 90 days. 5.05% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Natera

A number of hedge funds have recently bought and sold shares of the business. Coatue Management LLC lifted its position in Natera by 1,446.1% during the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock valued at $603,270,000 after purchasing an additional 2,463,008 shares during the period. Wellington Management Group LLP boosted its holdings in Natera by 94.7% in the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock worth $1,140,026,000 after purchasing an additional 2,420,263 shares during the last quarter. Norges Bank bought a new stake in Natera in the 4th quarter worth approximately $372,398,000. JPMorgan Chase & Co. lifted its holdings in shares of Natera by 10.5% during the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock valued at $2,944,800,000 after buying an additional 1,225,420 shares during the period. Finally, AQR Capital Management LLC boosted its stake in shares of Natera by 39.0% in the 3rd quarter. AQR Capital Management LLC now owns 2,400,065 shares of the medical research company’s stock worth $386,338,000 after buying an additional 673,315 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.